BioPharmSignal logoBioPharmSignal

Biotech News

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Rani Therapeutics (RANI)Rani TherapeuticsClinical readout

- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill ® capsule versus subcutaneous injection - SAN JOSE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings,

Related news

RANIRani Therapeutics2026-07-15 12:00 EST

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

RANIRani Therapeutics2026-05-15 20:05 EST

Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition

View all latest news

Rani Therapeutics

Rani Therapeutics is a drug-delivery company focused on oral delivery of biologics and other therapeutics. Its platform aims to replace injections with swallowable delivery.

Recent company news

RANIRani Therapeutics2026-08-04 12:00 EST

Rani Therapeutics Appoints Michelle Gilson to Board of Directors

RANIRani Therapeutics2026-07-20 20:05 EST

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RANIRani Therapeutics2026-07-15 12:00 EST

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

RANIRani Therapeutics2026-07-09 20:05 EST

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

RANIRani Therapeutics2026-06-29 12:00 EST

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

Stock data

Close
0.78 USD
Market cap
96.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States